UBS has recently initiated Nurix Therapeutics Inc (NRIX) stock to Buy rating, as announced on October 24, 2024, according to Finviz. Earlier, on October 11, 2024, Jefferies had initiated the stock to Buy, setting a price target of $41. Robert W. Baird also resumed Outperform rating with a price target of $26. Additionally, Truist initiated Buy rating on July 31, 2024, with a target price of $36. Oppenheimer analysts, in their report published on June 26, 2023, also resumed Outperform rating and set a price target of $25 for Nurix Therapeutics Inc’s stock. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.
Sponsored
Nurix Therapeutics Inc (NRIX) Stock Trading Recap
On Friday, Nurix Therapeutics Inc (NRIX) stock saw a decline, ending the day at $24.47 which represents a decrease of $-0.11 or -0.45% from the prior close of $24.58. The stock opened at $24.45 and touched a low of $23.93 during the day, reaching a high of $24.75. The volume of shares traded was 0.62 million falling short of the average volume of 0.68 million.
NRIX Stock Performance and Moving Averages
In recent trading, Nurix Therapeutics Inc (NRIX) stock price has shown some volatility, fluctuating -6.85% over the last five trades and 12.92% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by 91.47%, and it has gained 18.07% in the previous three months. Currently, NRIX is trading at 0.15%, 1.13%, and 37.85% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.
As of the latest trading close, NRIX, a Healthcare sector stock, is trading -11.34% below its 52-week high but remains 393.35% above its 52-week low. The Average True Range (ATR) (14 days) of 1.35 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.
Nurix Therapeutics Inc’s Profitability and Valuation Ratios
Nurix Therapeutics Inc’s profitability metrics reveal strong financial health. The company currently boasts an operating margin of -343.30% and a profit margin of -313.65%, with a gross margin of 91.47%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.
In terms of valuation, Nurix Therapeutics Inc’s market capitalization stands at $1.73 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. Additionally, the Price-to-Sales Ratio is 30.72, reflecting the market’s valuation of the company’s sales, while the Price-to-Book Ratio is 4.36, comparing the market value to the company’s book value.
Understanding Insider Trading
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 1.67% of Nurix Therapeutics Inc (NRIX)’s shares, while financial institutions hold 91.85%.
Notable insider trades include Ring Christine, Chief Legal Officer at Nurix Therapeutics Inc (NRIX), who sold 5760 shares on Nov 01 ’24, at $24.28 each, totaling $0.14 million. On Oct 30 ’24, Ring Christine, Chief Legal Officer, sold 4182 shares for $24.3 each, amounting to $0.10 million. Additionally, on Oct 01 ’24, Ring Christine sold 5760 shares at $22.23 each, generating $0.13 million.
